Inhibition of acyl-CoA cholesterol acyltransferase by F12511 (eflucimibe): Could it be a new antiatherosclerotic therapeutic?

Cardiovascular Therapeutics

Volumn 26, Issue 1, 2008, Pages 65-74

  López Farré, Antonio José ^a   Sacristán, Daniel ^a   Zamorano León, José J ^a   San Martín, Nuria ^a   Macaya, Carlos ^a  

^a HOSPITAL CLÍNICO SAN CARLOS   (Spain)

Author keywords

ACAT inhibitors; Atherosclerosis; Cholesteryl esters; Eflucimibe

Indexed keywords

ACYL COENZYME A CHOLESTEROL ACYLTRANSFERASE 1; ACYL COENZYME A CHOLESTEROL ACYLTRANSFERASE 2; AVASIMIBE; C 1976; CHOLESTEROL ACYLTRANSFERASE; CHOLESTEROL ACYLTRANSFERASE INHIBITOR; CP 113818; EFLUCIMIBE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PLACEBO; UNCLASSIFIED DRUG;

ATHEROSCLEROSIS; CLINICAL TRIAL; DRUG EFFECT; DRUG INHIBITION; ENDOTHELIAL DYSFUNCTION; HUMAN; NONHUMAN; PRIORITY JOURNAL; REVIEW;

ANILIDES; ANIMALS; ATHEROSCLEROSIS; CLINICAL TRIALS AS TOPIC; ENZYME INHIBITORS; HUMANS; STEROL O-ACYLTRANSFERASE;

EID: 47049102055     PISSN: 17555914     EISSN: 17555922     Source Type: Journal    
DOI: 10.1111/j.1527-3466.2007.00030.x     Document Type: Review

References (53)

1. Aikawa M, Rabkin E, Okada Y, Voglic SJ, Clinton SK, Brincerhoff CE, Sukhova GK, Libby P (1998) Lipid lowering by dict reduces matrix metalloproteinase activity and increases collagen content of rabbit atheroma. A potential mechanism of lesion stabilization. Circulation 83 : 378 387.
2. Aikawa M, Sugiyama S, Christopher CH, Voglic SJ, Rabkin E, Fukumoto Y, Schoen FJ, Witztum JL, Libby P (2002) Lipid lowering reduces oxidative stress and endothelial cell activation in rabbit atheroma. Circulation 106 : 1390 1396.
3. Anderson RA, Joyce C, Davis M, Reagan JW, Clark M, Shelness GS, Rudel LL (1998) Identification of a form of acyl-CoA: cholesterol acyltransferase specific to liver and intestine in nonhuman primates. J Biol Chem 273 : 26747 26754.
4. Aukrust P, Müller F, Ueland T, Berget T, Aaser E, Brunsvig A, Solum NO, Forfang K, Frøland SS, Gullestad L (1999) Enhanced levels of soluble and membrane-bound CD40 ligand in patients with unstable angina. Possible reflection of T lymphocyte and platelet involvement in the pathogenesis of acute coronary syndromes. Circulation 100 : 614 620.
5. Bernard DW, Rodriguez A, Rothblat GH, Glick JM (1990) Influence of high density lipoprotein in esterified cholesterol stores in macrophages and hepatoma cells. Ateriosclerosis 10 : 135 144.
6. Bocan TM, Mueller SB, Mazur MJ, Uhlendorf PD, Brown EQ, Kieft KA (1993) The relationship between the degree of dietary-induced hypercholesterolemia in the rabbit and atherosclerotic lesion formation. Atherosclerosis 102 : 9 22.
7. Burnett JR (2003) Eflucimibe. Pierre Fabre/Eli Lilly. Curr Opin Investig Drugs 4 : 347 351.
8. Cadigan KM, Heider JG, Chang TY (1988) Isolation and characterization of Chinese hamster ovary cell mutans deficient in acyl-coenzyme A:cholesterol acyltransferase activity. J Biol Chem 263 : 274 282.
9. Cases S, Novak S, Zheng YW, Myers HM, Lear SR, Sande E, Welch CB, Lusis AJ, Spencer TA, Krause BR, et al 1998) ACAT-2, a second mammalian acyl-CoA: cholesterol acyltransferase. Its cloning, expression and characterization. J Biol Chem 273 : 26755 26764.
10. Chang CC, Sakashita N, Ornvold K, Lee O, Chang ET, Dong R, Lin S, Lee CY, Strom SC, Kashyap R, et al 2000) Immunological quantitation and localization of ACAT-1 and ACAT-2 in human liver and small intestine. J Biol Chem 275 : 28083 28092.
11. Dominick MA, Bobrowski WA, MacDonald JR, Gough AW (1993) Morphogenesis of a zone-specific adrenocortical cytotoxicity in guinea pigs administered PD 132301-2, an inhibitor of acyl-CoA:cholesterol acyltransferase. Toxicol Pathol 21 : 54 62.
12. Dominick MA, McGuire EJ, Reindel JF, Bobrowski WF, Bocan TM, Gough AW (1993) Subacute toxicity of a novel inhibitor of acyl-CoA: cholesterol acyltransferase in beagle dogs. Fundam Appl Toxicol 20 : 217 224.
13. Felton CV, Crook D, Davies MJ, Olivier MF (1997) Relation of plaque lipid composition and morphology to the stability of human aortic plaques. Aterioscler Thromb Vasc Biol 17 : 1337 1345.
14. Guzik TJ, Harrison DG (2006) Vascular NADPH oxidases as drug targets for novel antioxidant strategies. Drug Discov Today 11 : 524 533.
15. Guzik TJ, Korbut R, Adamek-Guzik T (2003) Nitric oxide and superoxide in inflammation and immune regulation. J Physiol Pharmacol 54 : 469 487.
16. Hainer JW, Terry JG, Connell JM, Zyruk H, Jenkins RM, Shand DL, Gillies PJ, Livak KJ, Hunt TL, Crouse JR (1994) Effect of the acyl-CoA:cholesterol acyltransferase inhibitor DuP 128 on cholesterol absorption and serum cholesterol in humans. Clin Pharmacol Ther 56 : 65 74.
17. Insull W Jr., Koren M, Davignon D, Sprecher H, Schrott L, Keilson A, Brown CA, Dujovne CA, Davidson MH, McLain R, et al 2001) Efficacy and short-term safety of a new ACAT inhibitor, avasimibe, on lipids, lipoproteins and apolipoproteins, in patients with combined hyperlipidemia. Atherosclerosis 157 : 137 144.
18. Jamal Z, Suffolk RA, Boyd GS, Suckling KE (1985) Metabolism of cholesteryl ester in monolayers of bovine adrenal cortical cells. Effect of an inhibitor of acyl-CoA: cholesterol acyltransferase. Biochim Biophys Acta 834 : 230 237.
19. Jialal I, Chait A (1989) Differences in the metabolism of oxidatively modified low density lipoprotein and acetylated low density lipoprotein by human endothelial cells: Inhibition of cholesterol esterification by oxidatively modified low density lipoprotein. J Lipid Res 30 : 1561 1568.
20. Jimenez A, Arriero MM, Lopez-Blaya A, Gonzalez-Fernandez F, Garcia R, Fortes J, Millas I, Velasco S, Sanchez De Miguel L, Rico L, et al 2001) Regulation of endothelial nitric oxide synthase expression in the vascular wall and in mononuclear cells from hypercholesterolemic rabbits. Circulation 104 : 1822 1830.
21. Jones P, Kafonek S, Laurora I, Hunninglake D (1998) Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin and fluvastatin in patients with hypercholesterolemia. Am J Cardiol 81 : 582 587.
22. Junquero D, Bruniquel F, N'Guyen X, Autin JM, Patoiseau JF, Degryse AD, Colpaert FC, Delhon A (2001) F 12511, a novel ACAT inhibitor, and atorvastatin regulate endogenous hypercolesterolemia in a synergistic manner in New Zealand rabbits fed a casein-enriched diet. Atherosclerosis 155 : 131 142.
23. Junquero D, Oms P, Carilla-Durand E, Autin J, Tarayre J, Degryse A, Patoiseau J, Colpaert FC, Delhon A (2001) Pharmacological profile of F 12511, a powerful and systemic acylcoenzyme A: cholesterol acyltransferase inhibitor. Biochem Pharmacol 61 : 97 108.
24. Junquero D, Pilon A, Carilla-Durand E, Patoiseau JF, Tarayre JP, Torpier G, Staels B, Fruchart JC, Colpaert FC, Clavey V, et al 2001) Lack of toxic effects of F 12511, a novel potent inhibitor of acyl-coenzyme A: cholesterol O-acyltransferase, on human adrenocortical cells in culture. Biochem Pharmacol 61 : 387 398.
25. Kaneko K, Uchida K, Kobayashi T, Miura K, Tanokura K, Hoshino K, Kato I, Onoue M, Yokokura T (2001) Sex-dependent toxicity of a novel acyl-CoA:cholesterol acyltransferase inhibitor, YIC-C8-434, in relation to sex-specific forms of cytochrome P450 in rats. Toxicol Sci 64 : 259 268.
26. Kellner-Weibel G, Jerome WG, Small DM, Warner GJ, Stoltenborg JK, Kearney MA, Corjay MH, Phillips MC, Rothblat GH (1998) Effects of intracellular free cholesterol accumulation on macrophage viability: A model for foam cell death. Arterioscler Thromb Vasc Biol 18 : 423 431.
27. Kock MM, De Meyer GR, Buysens R, Kanaapen MW, Bult H, Herman AG (1998) Cell composition, replication and apoptosis in the atherosclerotic plaques after 6 months of cholesterol withdrawal. Circ Res 83 : 378 387.
28. Lada AT, Davis M, Kent C, Chapman J, Tomoda H, Omura S, Rudel LL (2004) Identification of ACAT-1 and ACAT-2 specific inhibitors using a novel, cell-based fluorescence assay: Individual ACAT uniqueness. J. Lipid Res 45 : 378 386.
29. Lee O, Chang CC, Lee W, Chang TY (1998) Immunodepletion experiments suggest that acyl-coenzyme A:cholesterol acyltransferase-1 (ACAT-1) protein plays a major catalytic role in adult human liver, adrenal gland, macrophages, and kidney, but not in intestines. J Lipid Res 39 : 1722 1727.
30. Leon C, Hill JS, Wasan KM (2005) Potential role of acyl-coenzyme A: cholesterol transferase (ACAT) inhibitors as hypolipidemic and antiatherosclerosis drugs. Pharm Res 22 : 1578 1588.
31. Libby P (1995) Molecular bases of the acute coronary syndrome. Circulation 91 : 2844 2850.
32. Matsuo M, Hashimoto M, Suzuki J, Iwanami K, Tomoi M, Shimomura K (1996) Difference between normal and WHHL rabbits in susceptibility to the adrenal toxicity of an acyl-CoA:cholesterol acyltransferase inhibitor, FR145237. Toxicol Appl Pharmacol 140 : 387 392.
33. Matsuo M, Ito F, Konto A, Aketa M, Tomoi M, Shimomura K (1995) Effect of FR145237, a novel ACAT inhibitor, on atherogenesis in cholesterol-fed and WHHL rabbits. Evidence for a direct effect on the arterial wall. Biochim Biophys Acta 1259 : 254 260.
34. Meiner VL, Cases S, Myers HM, Sande ER, Bellosta S, Schambelan M, Pitas RE, McGuire J, Herz J, Farese RV (1996) Disruption of the acyl-CoA:cholesterol acyltransferase gene in mice: Evidence suggesting multiple cholesterol esterification enzymes in mammals. Proc Natl Acad Sci U S A 93 : 14041 14046.
35. Miyazaki A, Sakashita N, Lee O, Takahashi K, Horiuchi S, Hakamata H, Morganelli PM, Chang CC, Chang TY (1998) Expression of ACAT-1 protein in human atherosclerotic lesions and cultured human monocytes-macrophages. Arterioscler Thromb Vasc Biol 18 : 1568 1574.
36. Moncada S, Higgs EA (2006) The discovery of nitric oxide and its role in vascular biology. Br J Pharmacol 147 : S193 S201.
37. Oelkers P, Behari A, Cromley D, Billheimer JT, Sturley SL (1998) Characterization of two human genes encoding acyl-CoA: cholesterol acyltransferase-related enzymes. J Biol Chem 273 : 26765 26771.
38. Peck RW, Wiggs R, Posner J (1995) The tolerability, pharmacokinetics and lack of effect on plasma cholesterol of 44C88, an Acyl CoA: cholesterol acyl transferase (ACAT) inhibitor with low bioavailability, in healthy volunteers. Eur. J. Clin. Pharmacol 49 : 243 249.
39. Ribet JP, Pena R, Chauvet A, Patoiseau JF, Autin JM, Segonds R, Basquin M, Autret JM (2002) Crystalline polymorphism of eflucimibe. Ann Pharm Fr 60 : 177 186.
40. Rival Y, Junquéro D, Bruniquel F, N'Guyen X, Fauré P, Pomiès JP, Degryse AD, Delhon A (2002) Anti-atherosclerotic properties of the acyl-coenzyme A: colesterol acyltransferase inhibitor F-12511 in casein-fed New Zealand rabbits. J Cardiovasc Pharmacol 39 : 181 191.
41. Ross AC, Go KJ, Heider JG, Rothblat GH (1984) Selective inhibition of acyl coenzyme A:cholesterol acyltranferase by compound 58-035. J Biol Chem 259 : 815 819.
42. Sahi J, Milad MA, Zheng X, Rose KA, Wang H, Stilgenbauer L, Gilbert D, Jolley S, Stern RH, LeCluyse EL (2003) Avasimibe induces CYP3A4 and multiple drug resistance protein 1 gene expression through activation of the pregnane X receptor. J Pharmacol Exp Ther 306 : 1027 1034.
43. Sakashita N, Miyazaki A, Takeya M, Horiuchi S, Chang CC, Chang TY, Takahashi K (2000) Localization of human acyl-coenzyme A: cholesterol acyltransferase-1 (ACAT-1) in macrophages and in various tissues. Am J Pathol 156 : 227 236.
44. ++ antagonist and ACAT inhibitors promote cholesterol efflux from macrophages from different mechanisms. I. Characterization of cellular lipid metabolism. Atheriosclerosis 8 : 46 56.
45. Schönbeck U, Varo N, Libby P, Buring J, Ridker PM (2001) Soluble CD40L and cardiovascular risk in women. Circulation 104 : 2266 2268.
46. Soeki T, Tamura Y, Shinohara H, Sakabe K, Onose Y, Fukuda N (2003) Increased soluble platelet/endothelial cell adhesion molecule-1 in the early stages of acute coronary syndromes. Int J Cardiol 90 : 261 268.
47. Suckling KE, Stange EF (1985) Role of acyl-CoA: cholesterol acyltransferase in cellular cholesterol metabolism. J Lipid Res 26 : 647 671.
48. Tabas I, Marathe S, Keesler GA, Beatini N, Shiratori Y (1996) Evidence that the initial up-regulation of phosphatidylcholine biosynthesis in free cholesterol-loaded macrophages is an adaptive response that prevents cholesterol-induced cellular necrosis. Proposed role of an eventual failure of this response in foam cell necrosis in advanced atherosclerosis. J Biol Chem 271 : 22773 22781.
49. Tardif JC, Grégoire J, L'Allier PL, Anderson TJ, Bertrand O, Reeves F, Title LM, Alfonso F, Schampaert E, Hassan A, et al 2004). Avasimibe and Progression of Lesions on UltraSound (A-PLUS) Investigators. Effects of the acyl coenzyme A: cholesterol acyltransferase inhibitor avasimibe on human atherosclerosis lesions. Circulation 110 : 3372 3377.
50. Toru S, Oelkers PM, Giattina MR, Worgall TS, Sturley SL, Deckelbaum JR (2001) Differential modulation of ACAT1 and ACAT2 transcription and activity by long chain free fatty acids in cultured cells. Biochemistry 40 : 4756 4762.
51. Vernetti LA, MacDonald JR, Wolfgang GH, Dominick MA, Pegg DG (1993) ATP depletion is associated with cytotoxicity of a novel lipid regulator in guinea pig adrenocortical cells. Toxicol Appl Pharmacol 118 : 30 38.
52. Warner GJ, Stoudt G, Bamberger M, Johnson WJ, Rothblat GH (1995) Cell toxicity induced by inhibition of acyl coenzyme A:cholesterol acyltransferase and accumulation of unesterified cholesterol. J Biol Chem 270 : 5772 5778.
53. Zamorano-León JJ, Fernández-Sánchez R, López Farré AJ, Lapuente-Tiana L, Alonso-Orgaz S, Sacristán D, Junquera D, Delhon A, Conesa A, Mateos-Cáceres PJ, et al 2006) Direct effect of F12511, a systemic inhibitor of acyl-CoA cholesterol acyltransferase on bovine aortic endothelial cells. J Cardiovasc Pharmacol 48 : 128 134.